Skip to main
  1. Stocks
  2. Immunocore Holdings
  3. Forecast
IMCR

Immunocore Holdings (IMCR) Stock Forecast & Price Target

Immunocore Holdings (IMCR) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 14%
Hold 43%
Sell 0%
Strong Sell 0%

Bulls say

Immunocore Holdings is supported by a strong commercial base in KIMMTRAK, which management says still shows no deterioration in underlying demand, with distributor inventory normalized and treatment duration holding at approximately 14 months, while the company estimates about 10% underlying revenue growth after normalizing for a $6.5 million stocking reversal and a prior-year extra selling week of about $5 million. Its pipeline adds meaningful upside: TEBE-AM has completed target enrollment in the 540-patient Phase 3 trial with overall-survival data now expected in 2Q27, and early brenetafusp combination data in metastatic uveal melanoma showed a 29% ORR, 24.1-month median response duration, and no grade ≥3 CRS, supporting a randomized Phase 2/3 DUET-UVEAL path. Beyond melanoma, IMC-P115C, IMC-S118AI, and IMC-U120AI broaden the platform’s long-term opportunity, while management’s continued investment across oncology, infectious disease, and autoimmune disease reinforces a diversified growth profile.

Bears say

Immunocore Holdings is facing a weaker fundamental outlook because the TEBE-AM readout shifted to 2Q27 after target enrollment was completed, delaying a key catalyst and pushing the timing of potential commercialization further out. That delay also forced a reset of launch assumptions, with U.S. KIMMTRAK in previously treated advanced cutaneous melanoma now modeled for 2028E and brenetafusp for 2030E, while 3Q26 KIMMTRAK revenue of $102.2 million missed estimates despite $901.3 million of cash, cash equivalents, and marketable securities. The company’s valuation is further pressured by a competitive backdrop, low 25% probability of success for brenetafusp, and risks around clinical execution, reimbursement, and dilution.

Immunocore Holdings (IMCR) has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 14% recommend Buy, 43% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunocore Holdings and is not a guaranteed prediction by Public.com or investment advice.

Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction

Get the latest Immunocore Holdings (IMCR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immunocore Holdings (IMCR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunocore Holdings (IMCR) Forecast

Analysts have given Immunocore Holdings (IMCR) a Buy based on their latest research and market trends.

According to 7 analysts, Immunocore Holdings (IMCR) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $52.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $52.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunocore Holdings (IMCR)


Immunocore Holdings (IMCR) Analyst Forecast & Price Prediction

Get the latest Immunocore Holdings (IMCR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Immunocore Holdings (IMCR)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IMCR stock data and trends